Table 1.
Clinical characteristics according to antibiotic exposure.
| Characteristic | Total | Antibiotics | No Antibiotics | p Value |
|---|---|---|---|---|
| Median (Range) or N (%) | Median (Range) or N (%) | Median (Range) or N (%) | ||
| Age (years) | 68 (29–2) | 67 (29–86) | 68 (35–92) | 0.27 |
| Gender | 0.8 | |||
| Female | 98 (39) | 54 (40) | 44 (38) | |
| Male | 153 (61) | 81 (60) | 72 (62) | |
| Race-ethnicity | 0.23 | |||
| Non-Hispanic white | 193 (77) | 108 (80) | 85 (73) | |
| Other | 58 (23) | 27 (20) | 31 (27) | |
| Cancer type | 0.26 | |||
| NSCLC | 133 (53) | 73 (54) | 60 (52) | |
| Melanoma | 47 (19) | 29 (21) | 18 (16) | |
| Other | 71 (28) | 33 (24) | 38 (33) | |
| BMI | 0.61 | |||
| <25 | 103 (41) | 53 (39) | 50 (43) | |
| ≥25 | 147 (59) | 81 (60) | 66 (57) | |
| Receipt of anti-CTLA4 | 0.33 | |||
| No | 221 (88) | 116 (86) | 105 (91) | |
| Yes | 30 (12) | 19 (14) | 11 (9) | |
| ECOG Performance status | 0.11 | |||
| 0–1 | 185 (74) | 95 (70) | 90 (78) | |
| 2–4 | 28 (11) | 19 (14) | 9 (8) | |
| Missing | 38 (15) | 21 (16) | 17 (14) | |
| Cancer Stage | 0.29 | |||
| I/II | 13 (5) | 6 (4) | 7 (6) | |
| III | 50 (20) | 32 (24) | 18 (16) | |
| IV | 161 (64) | 84 (62) | 77 (66) | |
| Missing | 27 (11) | 13 (10) | 14 (12) |
BMI, body mass index; CTLA4, cytotoxic T lymphocyte antigen 4; ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.